Ioannou Adam, Patel Rishi K, Razvi Yousuf, Porcari Aldostefano, Knight Daniel, Martinez-Naharro Ana, Kotecha Tushar, Venneri Lucia, Chacko Liza, Brown James, Manisty Charlotte, Moon James, Wisniowski Brendan, Lachmann Helen, Wechelakar Ashutosh, Whelan Carol, Kellman Peter, Hawkins Philip N, Gillmore Julian D, Fontana Marianna
National Amyloidosis Centre, University College London, Royal Free Campus, London, United Kingdom.
St Bartholomew's Hospital, London, United Kingdom.
JACC Cardiovasc Imaging. 2023 Apr;16(4):464-477. doi: 10.1016/j.jcmg.2022.07.008. Epub 2022 Sep 14.
Bone scintigraphy is extremely valuable when assessing patients with suspected cardiac amyloidosis (CA), but the clinical significance and associated phenotype of different degrees of cardiac uptake across different types is yet to be defined.
This study sought to define the phenotypes of patients with varying degrees of cardiac uptake on bone scintigraphy, across multiple types of systemic amyloidosis, using extensive characterization comprising biomarkers as well as echocardiographic and cardiac magnetic resonance (CMR) imaging.
A total of 296 patients (117 with immunoglobulin light-chain amyloidosis [AL], 165 with transthyretin amyloidosis [ATTR], 7 with apolipoprotein AI amyloidosis [AApoAI], and 7 with apolipoprotein AIV amyloidosis [AApoAIV]) underwent deep characterization of their cardiac phenotype.
AL patients with grade 0 myocardial radiotracer uptake spanned the spectrum of CMR findings from no CA to characteristic CA, whereas AL patients with grades 1 to 3 always produced characteristic CMR features. In ATTR, the CA burden strongly correlated with myocardial tracer uptake, except in Ser77Tyr. AApoAI presented with grade 0 or 1 and disproportionate right-sided involvement. AApoAIV always presented with grade 0 and characteristic CA. AL grade 1 patients (n = 48; 100%) had characteristic CA, whereas only ATTR grade 1 patients with Ser77Tyr had characteristic CA on CMR (n = 5; 11.4%). After exclusion of Ser77Tyr, AApoAI, and AApoAIV, CMR showing characteristic CA or an extracellular volume of >0.40 in patients with grade 0 to 1 cardiac uptake had a sensitivity and specificity of 100% for AL.
There is a wide variation in cardiac phenotype between different amyloidosis types across different degrees of cardiac uptake. The combination of CMR and bone scintigraphy can help to define the diagnostic differentials and the clinical phenotype in each individual patient.
骨闪烁显像在评估疑似心脏淀粉样变性(CA)患者时具有极高价值,但不同类型中不同程度心脏摄取的临床意义及相关表型尚未明确。
本研究旨在通过包括生物标志物以及超声心动图和心脏磁共振(CMR)成像在内的广泛特征描述,确定多种类型系统性淀粉样变性患者骨闪烁显像时不同程度心脏摄取的表型。
共296例患者(117例免疫球蛋白轻链淀粉样变性[AL]、165例转甲状腺素蛋白淀粉样变性[ATTR]、7例载脂蛋白AI淀粉样变性[AApoAI]和7例载脂蛋白AIV淀粉样变性[AApoAIV])接受了心脏表型的深入特征描述。
心肌放射性示踪剂摄取为0级的AL患者涵盖了从无CA到特征性CA的CMR表现范围,而1至3级的AL患者总是呈现特征性CMR特征。在ATTR中,除Ser77Tyr外,CA负荷与心肌示踪剂摄取密切相关。AApoAI表现为0级或1级且右侧受累不成比例。AApoAIV总是表现为0级和特征性CA。AL 1级患者(n = 48;100%)有特征性CA,而CMR上只有Ser77Tyr的ATTR 1级患者有特征性CA(n = 5;11.4%)。排除Ser77Tyr、AApoAI和AApoAIV后,CMR显示心脏摄取为0至1级的患者中特征性CA或细胞外容积>0.40对AL的敏感性和特异性为100%。
不同淀粉样变性类型在不同程度心脏摄取时心脏表型存在广泛差异。CMR和骨闪烁显像相结合有助于明确每个患者的诊断差异和临床表型。